ANA AMELIA FIALHO DE OLIVEIRA HOFF
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
conferenceObject Effect of age and lenvatinib treatment on overall survival for patients with I-131-refractory differentiated thyroid cancer in SELECT(2015) BROSE, Marcia S.; SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori J.; ROBINSON, Bruce; ELISEI, Rossella; NEWBOLD, Kate; KIYOTA, Naomi; HOFF, Ana O.; DUTCUS, Corina; SONG, James; SHERMAN, Steven I.; TAYLOR, Matthew Hiram- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer(2015) SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori J.; ROBINSON, Bruce; BROSE, Marcia S.; ELISEI, Rossella; HABRA, Mouhammed Amir; NEWBOLD, Kate; SHAH, Manisha H.; HOFF, Ana O.; GIANOUKAKIS, Andrew G.; KIYOTA, Naomi; TAYLOR, Matthew H.; KIM, Sung-Bae; KRZYZANOWSKA, Monika K.; DUTCUS, Corina E.; HERAS, Begona de las; ZHU, Junming; SHERMAN, Steven I.Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor a, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131). Methods In our phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 patients to receive placebo. At the time of disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was progression-free survival. Secondary end points included the response rate, overall survival, and safety. Results The median progression-free survival was 18.3 months in the lenvatinib group and 3.6 months in the placebo group (hazard ratio for progression or death, 0.21; 99% confidence interval, 0.14 to 0.31; P<0.001). A progression-free survival benefit associated with lenvatinib was observed in all prespecified subgroups. The response rate was 64.8% in the lenvatinib group (4 complete responses and 165 partial responses) and 1.5% in the placebo group (P<0.001). The median overall survival was not reached in either group. Treatment-related adverse effects of any grade, which occurred in more than 40% of patients in the lenvatinib group, were hypertension (in 67.8% of the patients), diarrhea (in 59.4%), fatigue or asthenia (in 59.0%), decreased appetite (in 50.2%), decreased weight (in 46.4%), and nausea (in 41.0%). Discontinuations of the study drug because of adverse effects occurred in 37 patients who received lenvatinib (14.2%) and 3 patients who received placebo (2.3%). In the lenvatinib group, 6 of 20 deaths that occurred during the treatment period were considered to be drug-related. Conclusions Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer. Patients who received lenvatinib had more adverse effects. (Funded by Eisai; SELECT ClinicalTrials.gov number, NCT01321554.)
conferenceObject Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial(2015) KIYOTA, N.; ROBINSON, B.; SHAH, M.; HOFF, A. O.; TAYLOR, M.; LI, D.; DUTCUS, C.; LEE, E. K.; KIM, S. B.; TAHARA, M.- Rapid Control of T3 Thyrotoxicosis in Patients with Metastatic Follicular Thyroid Cancer Treated with Lenvatinib(2015) DANILOVIC, Debora Lucia Seguro; CAMARGO, Rosalinda Yossie Asato de; CASTRO JR., Gilberto; PAPADIA, Carla; MARUI, Suemi; HOFF, Ana Oliveira
conferenceObject EFFICACY AND SAFETY OF LENVATINIB FOR THE TREATMENT OF PATIENTS WITH I-131-REFRACTORY DIFFERENTIATED THYROID CANCER WITH AND WITHOUT PRIOR VEGF-TARGETED THERAPY(2015) NEWBOLD, Kate; ELISEI, Rosella; TAYLOR, Matthew Hiram; KRZYZANOWSKA, Monika; SHAH, Manisha H.; HOFF, Ana O.; ROBINSON, Bruce; DUTCUS, Corina; SONG, James; HUGHES, Brett; HABRA, Mouhammed AmirconferenceObject Efficacy and safety of lenvatinib for the treatment of patients with I-131-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.(2015) NEWBOLD, Kate; ELISEI, Rossella; TAYLOR, Matthew Hiram; KRZYZANOWSKA, Monika K.; SHAH, Manisha H.; HOFF, Ana O.; ROBINSON, Bruce; DUTCUS, Corina; SONG, James; HABRA, Mouhammed Amir- AACE/ACE DISEASE STATE CLINICAL REVIEW: PANCREATIC NEUROENDOCRINE INCIDENTALOMAS(2015) HERRERA, Miguel F.; AKERSTROM, Goran; ANGELOS, Peter; GRANT, Clive S.; HOFF, Ana O.; PANTOJA, Juan Pablo; PEREZ-JOHNSTON, Rocio; SAHANI, Dushyant V.; WONG, Richard J.; RANDOLPH, GregoryIncidental detection of pancreatic neuroendocrine tumors (PNETs) has substantially increased over the last decade due to widespread use of advanced imaging studies. Reliable initial imaging-based characterization is crucial for the differential diagnosis from other exocrine neoplasms and to determine the appropriate management plan. Measurements of chromogranin A, pancreatic polypeptide, and calcitonin are recommended for the biochemical evaluation. A thorough medical history needs to be performed to rule out multiple endocrine neoplasia (MEN) type 1. The European Neuroendocrine Tumor Society (ENETS)/Tumor Node Metastasis (TNM) staging system together with a grading based on the Ki-67 proliferation index and mitotic counts has proven to give more appropriate prognostic information than the World Health Organization (WHO)/American Joint Committee on Cancer (AJCC) TNM staging but may still fail to safely differentiate benign from malignant lesions. Poorly differentiated PNETs generally present with metastases and are rarely amenable for resection. Well-or intermediately differentiated tumors >= 2 cm with imaging evidence of malignancy or with a Ki-67 > 2% should be resected. It has been suggested that non-MEN related, nonfunctioning, and asymptomatic PNETs < 2 cm with a Ki-67 index >= 2% carry a low risk of metastasis and may be observed in the absence of clinical or radiologic criteria of malignancy or progression, especially in older patients. However, because metastases may occur with long delay with smaller PNETS, physicians should consider patient age, lesion location, and the risks of operation, and patients not undergoing surgery need to be closely followed closely.
bookPart Câncer de tireoide(2015) FONSECA, Leonardo Gomes da; HOFF, Ana Amélia O.; CASTRO JUNIOR, Gilberto deconferenceObject EFFECT OF AGE AND LENVATINIB TREATMENT ON OVERALL SURVIVAL FOR PATIENTS WITH I-131- REFRACTORY DIFFERENTIATED THYROID CANCER IN SELECT(2015) BROSE, Marcia; SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori; ROBINSON, Bruce; ELISEI, Rossella; NEWBOLD, Kate; KIYOTA, Naomi; HOFF, Ana O.; DUTCUS, Corina; SONG, James; HUGHES, Brett; SHERMAN, Steven; TAYLOR, Matthew Hiram